Sensei Biotherapeutics announced the appointment of Stephanie Krebs, MS, MBA, as Chief Business Officer. Krebs joins Sensei from SNIPR Biome, a clinical-stage biotechnology company where, as Chief Business Officer.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SNSE:
- Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business Officer
- Sensei Biotherapeutics to Present Initial Clinical Data from Dose Escalation Trial of SNS-101 at 2023 SITC Annual Meeting
- Sensei Biotherapeutics Presents Trial-in-Progress Poster for Phase 1/2 Clinical Study of SNS-101 at ESMO 2023
- Sensei Biotherapeutics presents poster for Phase 1/2 study of SNS-101
- Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron’s Libtayo®
